To assess the efficacy of peri-operative beta-blockade in reducing myocardial ischaemia, myocardial infarction, and cardiac or all-cause mortality.
groups; completeness of follow-up; and important confounders or biases. The authors do not state how the papers were assessed for validity, or how many of the reviewers performed the validity assessment.
Data extraction
The authors do not state how the data were extracted for the review, or how many of the reviewers performed the data extraction.
The information tabulated in the review included: author and year of publication; the inclusion and exclusion criteria for the participants; beta-blocker regimen; target heart rate (if set); and findings.
Methods of synthesis
How were the studies combined? A narrative synthesis was undertaken.
How were differences between studies investigated? Differences were discussed in the text of the review, with particular reference to the differences in baseline cardiac risk between the studies.
Results of the review
Five RCTs (586 patients) were included.
Peri-operative ischaemia (4 RCTs). Three of the four RCTs found a statistically-significant reduction in peri-operative ischaemia among the patients treated with beta-blockers. The number-needed-to-treat ranged from 2.5 to 6.7. The fourth study found a non significant reduction in ischaemia in the treated group. It also reported a lower rate of ischaemia in the control group of 15%, compared with rates ranging from 28 to 73% in the control groups of studies finding a statistical difference.
Cardiac events and mortality (4 RCTs).
The number-needed-to-treat, where reported, ranged from 3.2 to 8.3.
One RCT involved 200 male veterans at risk of cardiac disease who were undergoing major noncardiac surgery. Ths study found no statistically-significant difference in the in-hospital cardiac or mortality, but found a relative reduction in all-cause mortality at 2 years in the treated group (2-year mortality was 9% versus 21%; p=0.02). These differences did not influence the results when adjusting for baseline differences between the treatment groups. Another RCT involved 112 high-risk patients undergoing vascular surgery. This study found that beta-blockade was associated with a significant reduction in peri-operative cardiac death (3.4% versus 17%; p=0.02) and nonfatal myocardial infarction (0% versus 17%; p<0.001). A further RCT involved 128 untreated hypertensive patients undergoing elective surgery; 30% of the patients in both treatment groups were already on beta-blockers. This study found that beta-blockade was associated with a reduction in post-operative myocardial infarction (2% versus 28%; p<0.001). The duration of followup was stated as being shorter than that for the other studies but no values were specified.
The fourth RCT involved 120 patients undergoing elective knee arthroplasty. This found no statistically-significant difference between the treatment groups in terms of the rates of post-operative myocardial infarction (2% versus 6%).
The aims were clearly stated and the inclusion criteria were defined in terms of the study design, intervention and outcomes. The methods used to determine ischaemia in the primary studies were not routinely described. By restricting the literature search to English language studies identified in one database, other relevant studies may have been omitted. In addition, the lack of an attempt to locate unpublished material raises the possibility of publication bias.
The methods used to select the studies were not described. The included studies were restricted to RCTs that were presumably placebo-controlled, although the control group was not explicitly specified a priori. Several aspects of validity were assessed and discussed in the text, and relevant data were extracted and tabulated clearly. However, the methods used to assess validity and extract the data were not described. It was not reported whether the analysis was conducted on an intention to treat basis.
A narrative synthesis was appropriate given the small number of studies in populations at varying risk of cardiac events. Potential causes of differences in the results between the studies were discussed.
The evidence presented appears to support the authors' conclusions, although only one study appears to have reported follow-up beyond the in-hospital period.
Implications of the review for practice and research
Practice: The authors state that the review suggests the use of peri-operative beta-blockers is associated with significant reductions in cardiac morbidity and mortality. They went on to state that the studies included a relatively small number of patients (less than 700) who were selected and not consecutively enrolled, making generalisability to other populations uncertain.
